Fig. S3. Gating strategy for identification of ILC2 populations based on GATA-3 expression, related to Fig. 1 A-C. ILC2 were identified by gating on CD45+ cells that were lineage neg (lin-) (Lineage cocktail: TCRβ, TCRγδ, CD5, CD19, CD11b, CD11c, FCεR1, GR-1, F4/80, and TER-119) lymphocytes that were additionally CD3e- and NKp46- and expressed GATA-3 as shown in **(A)**. **(B)** shows % of GATA-3+ ILC2 in lungs of mock, Alt and IL-33 treated mice which were further quantified in number as shown in **(C)** and co-expressed IL-13 and IL-5 **(D)**. ILC2 were further evaluated for percent expression of CD90.2 **(E)**, KLRG-1**(F)**, CD127 **(G)** and CD25 **(H)**. Data shown for are from one of 4 independent experiments with a total of n ≥ 6 mice per group, **$P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$.